Cargando…
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
BACKGROUND: Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic differences among patients with ILC, invasive ductal carcinoma...
Autores principales: | Davis, Andrew A., Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J., Velimirovic, Marko, Hensing, Whitney L., Bucheit, Leslie, Shah, Ami N., D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S., Denault, Elyssa N., Bagegni, Nusayba A., Opyrchal, Mateusz, Ademuyiwa, Foluso O., Bose, Ron, Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637866/ https://www.ncbi.nlm.nih.gov/pubmed/36332363 http://dx.doi.org/10.1016/j.ebiom.2022.104316 |
Ejemplares similares
-
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
por: Gerratana, Lorenzo, et al.
Publicado: (2023) -
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019) -
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
por: Bagegni, Nusayba A, et al.
Publicado: (2022) -
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer
por: D’Amico, Paolo, et al.
Publicado: (2021) -
Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ
por: Dania, Vanessa, et al.
Publicado: (2019)